Page last updated: 2024-11-03

prazosin and Neoplasms

prazosin has been researched along with Neoplasms in 9 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation."3.71Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001)
"Presently cancer is a grave health issue with predominance beyond restrictions."2.72Therapeutic progression of quinazolines as targeted chemotherapeutic agents. ( Bansal, R; Malhotra, A, 2021)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's2 (22.22)29.6817
2010's4 (44.44)24.3611
2020's2 (22.22)2.80

Authors

AuthorsStudies
Dolusić, E1
Larrieu, P1
Moineaux, L1
Stroobant, V1
Pilotte, L1
Colau, D1
Pochet, L1
Van den Eynde, B1
Masereel, B1
Wouters, J1
Frédérick, R1
Bansal, R1
Malhotra, A1
Kozik, P1
Gros, M1
Itzhak, DN1
Joannas, L1
Heurtebise-Chrétien, S1
Krawczyk, PA1
Rodríguez-Silvestre, P1
Alloatti, A1
Magalhaes, JG1
Del Nery, E1
Borner, GHH1
Amigorena, S1
Fuchs, R2
Stracke, A2
Holzmann, V1
Luschin-Ebengreuth, G1
Meier-Allard, N1
Ebner, N2
Lassacher, TM1
Absenger-Novak, M2
Fröhlich, E1
Schittmayer, M2
Cano Crespo, S1
Palacin, M1
Rinner, B1
Birner-Gruenberger, R2
Zeller, CW1
Raninger, AM1
Kueznik, T1
Friedman, GD1
Udaltsova, N1
Habel, LA1
Robey, RW1
Shukla, S1
Finley, EM1
Oldham, RK1
Barnett, D1
Ambudkar, SV1
Fojo, T1
Bates, SE1
Riffkin, CD1
Chung, R1
Wall, DM1
Zalcberg, JR1
Cowman, AF1
Foley, M1
Tilley, L1
Chrischilles, E1
Rubenstein, L1
Chao, J1
Kreder, KJ1
Gilden, D1
Shah, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596]Phase 463 participants (Actual)Interventional2015-10-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for prazosin and Neoplasms

ArticleYear
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
    European journal of medicinal chemistry, 2021, Feb-05, Volume: 211

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure;

2021

Trials

1 trial available for prazosin and Neoplasms

ArticleYear
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
    Biochemical pharmacology, 2008, Mar-15, Volume: 75, Issue:6

    Topics: Adenosine Triphosphatases; Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transport

2008

Other Studies

7 other studies available for prazosin and Neoplasms

ArticleYear
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
    Journal of medicinal chemistry, 2011, Aug-11, Volume: 54, Issue:15

    Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line; Drug Design; Enzyme Inhibitors;

2011
Small Molecule Enhancers of Endosome-to-Cytosol Import Augment Anti-tumor Immunity.
    Cell reports, 2020, 07-14, Volume: 32, Issue:2

    Topics: Animals; Antigens; Antineoplastic Agents; beta-Lactamases; Biological Transport; Cross-Priming; Cyto

2020
Prazosin induced lysosomal tubulation interferes with cytokinesis and the endocytic sorting of the tumour antigen CD98hc.
    Biochimica et biophysica acta. Molecular cell research, 2018, Volume: 1865, Issue:9

    Topics: Cell Survival; Cytokinesis; Endocytosis; Fusion Regulatory Protein 1, Heavy Chain; Gene Expression R

2018
The cytotoxicity of the α1-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P.
    Toxicology, 2015, Dec-02, Volume: 338

    Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Pro

2015
Norepinephrine antagonists and cancer risk.
    International journal of cancer, 2011, Feb-01, Volume: 128, Issue:3

    Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto

2011
Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.
    Biochemical pharmacology, 1996, Nov-22, Volume: 52, Issue:10

    Topics: Affinity Labels; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sit

1996
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
    Clinical therapeutics, 2001, Volume: 23, Issue:5

    Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor

2001